CA-20260930-7480Exam Essential

Department of Pharmaceuticals Approves 41 R&D Projects Worth ₹1,600 Crore under PRIP Scheme

30 Sept 2026

4 min read

Source:PIB India (Press Information Bureau)

The Department of Pharmaceuticals has approved 41 research and development projects worth approximately ₹1,600 crore under the first round of the PRIP scheme. This initiative aims to catalyze private sector investments and transition India's pharmaceutical ecosystem from a volume-driven model to an innovation-led paradigm.

Key Highlights

Catalyzes an anticipated private sector co-investment of ₹3,020 crore, pushing the aggregate R&D outlay for these approved projects to ₹4,620 crore.
The approved portfolio comprises 12 early-stage initiatives and 29 advanced-stage projects, distributed among startups, MSMEs (19 projects), and major industry conglomerates (22 projects).
Focuses heavily on therapeutic priorities with 27 projects dedicated to novel drugs, 5 to complex generics and biosimilars, and 9 targeting advanced medical devices.
Includes cutting-edge technological frameworks such as antibacterial agents for multi-drug resistant gram-negative infections, exosome-based regenerative therapies, in-vivo CAR-T platforms, and programmable RNA-targeting antiviral technologies.
Incorporates a strategic framework specifically prioritizing neglected tropical diseases, rare genetic disorders, antimicrobial resistance (AMR), and indigenous pathogen surveillance.

Exam Quick Facts

Nodal Ministry / Dept

Ministry of Chemicals and Fertilizers (Department of Pharmaceuticals)

Key Bodies

ICMR (Indian Council of Medical Research), Department of Biotechnology (DBT), CDSCO (Central Drugs Standard Control Organization)

Constitutional & Legal Context

National Intellectual Property Rights (IPR) Policy; Drugs and Cosmetics Act, 1940

Static GK Connection

India ranks among the top global producers of generic medicines by volume; however, transition towards API (Active Pharmaceutical Ingredient) self-reliance and Biologics R&D constitutes a major objective under Atmanirbhar Bharat.

In-Depth Editorial Analysis

The Promotion of Research and Innovation in Pharmaceuticals (PRIP) scheme represents a critical strategic pivot in India's industrial and healthcare policy. Historically, India has maintained a formidable global standing as the 'Pharmacy of the World' due to its prowess in generic drug manufacturing and volume-driven production. However, moving up the global value chain requires a structural transition toward intellectual property creation, drug discovery, and indigenous medical technology design. The approval of 41 diverse projects under the scheme's maiden round underscores a deliberate policy intervention to de-risk high-investment, high-risk pharmaceutical research for domestic players.

Official Reference:PIB India (Press Information Bureau)

Daily Practice MCQs

Exam-standard questions tailored for SSC, Banking & PSC exams

3 Questions

Level 1: Direct Factual (SSC / Railways)

Q1.How many pharma and medtech innovation projects were approved in the first round of the PRIP scheme?

Level 2: Conceptual Bridge (Banking / State PSC)

Q2.The PRIP scheme, which aims to shift India's pharmaceutical industry from a volume-based model to an innovation-driven model, is spearheaded by which nodal government department?

Level 3: Multi-Statement (UPSC / State PCS)

Q3.Consider the following statements regarding the PRIP scheme: 1. It exclusively funds large-scale multinational pharmaceutical corporations and excludes startups and MSMEs. 2. The approved portfolio under its first round includes projects focusing on novel drug discovery, complex generics, and medical devices. Which of the statements given above is/are correct?